Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Net Income towards Common Stockholders: 2010-2025

Historic Net Income towards Common Stockholders for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Sep 2025 value amounting to $52.8 million.

  • Catalyst Pharmaceuticals' Net Income towards Common Stockholders rose 20.28% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.1 million, marking a year-over-year increase of 65.79%. This contributed to the annual value of $163.4 million for FY2024, which is 174.43% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Net Income towards Common Stockholders is $52.8 million, which was up 1.30% from $52.1 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $56.7 million for Q1 2025, and its period low was -$30.8 million during Q3 2023.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was $40.8 million (2024), whereas its average is $35.0 million.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Net Income towards Common Stockholders plummeted by 235.24% in 2023 and then spiked by 242.65% in 2024.
  • Catalyst Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at $9.3 million in 2021, then surged by 173.62% to $25.5 million in 2022, then fell by 9.82% to $23.0 million in 2023, then skyrocketed by 141.33% to $55.4 million in 2024, then climbed by 20.28% to $52.8 million in 2025.
  • Its last three reported values are $52.8 million in Q3 2025, $52.1 million for Q2 2025, and $56.7 million during Q1 2025.